scholarly journals Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Tao Yin ◽  
Guoping Wang ◽  
Tinghong Ye ◽  
Yongsheng Wang
Keyword(s):  
Breast Cancer ◽  
Inflammatory Drug ◽  
Immune Modulator ◽  
Anti Inflammatory ◽  
Breast Cancer Inhibition ◽  
Cancer Inhibition

scholarly journals Nonsteroidal anti‐inflammatory drug use and breast cancer risk in a European prospective cohort study

2018 ◽  
Vol 143 (7) ◽  
pp. 1688-1695 ◽  
Author(s):  
Manon Cairat ◽  
Agnès Fournier ◽  
Neil Murphy ◽  
Carine Biessy ◽  
Augustin Scalbert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Breast Cancer Risk ◽  
Drug Use ◽  
Cancer Risk ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Inflammatory Drug ◽  
Anti Inflammatory

The Relationship of Nonsteroidal Anti-inflammatory Drug Use to the Risk of Breast Cancer

1999 ◽  
Vol 29 (2) ◽  
pp. 72-76 ◽  
Author(s):  
Patricia F. Coogan ◽  
Sowmya R. Rao ◽  
Lynn Rosenberg ◽  
Julie R. Palmer ◽  
Brian L. Strom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Use ◽  
Inflammatory Drug ◽  
Anti Inflammatory ◽  
Relationship Of ◽  
The Relationship

scholarly journals Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes

2016 ◽  
Vol 128 (8) ◽  
pp. 2895-2900 ◽  
Author(s):  
Janine N. Boodram ◽  
Iain J. Mcgregor ◽  
Peter M. Bruno ◽  
Paul B. Cressey ◽  
Michael T. Hemann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Breast Cancer Stem Cell ◽  
Inflammatory Drug ◽  
Anti Inflammatory

scholarly journals Combinatorial epigenetic mechanisms and efficacy of early breast cancer inhibition by nutritive botanicals

Epigenomics ◽  
2016 ◽  
Vol 8 (8) ◽  
pp. 1019-1037 ◽  
Author(s):  
Yuanyuan Li ◽  
Phillip Buckhaults ◽  
Xiangqin Cui ◽  
Trygve O Tollefsbol
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Epigenetic Mechanisms ◽  
Breast Cancer Inhibition ◽  
Cancer Inhibition

Dual Aromatase-Sulphatase Inhibitors (DASIs) for the Treatment of Hormone Dependent Breast Cancer

2021 ◽  
Vol 21 ◽  
Author(s):  
Laxmi Banjare ◽  
Akhlesh Kumar Jain ◽  
Suresh Thareja
Keyword(s):  
Breast Cancer ◽  
Dehydroepiandrosterone Sulfate ◽  
Develop Breast Cancer ◽  
Estrone Sulfate ◽  
Cancer Tissues ◽  
Breast Cancer Inhibition ◽  
Estrogen Biosynthesis ◽  
Breast Tissues ◽  
Cancer Inhibition

: Breast cancer is the most frequent diagnosed cancer in women and the second most common form of cancer, causing death after lung cancer, all across the globe at an alarming rate. The level of estrogens, in breast cancer tissues of postmenopausal women is 10-40 folds higher than the non-carcinogenic breast tissues. As a result of this greater level of estrogen, breast tissue becomes more prone to develop breast cancer; mainly estradiol plays a significant role in the initiation and development of hormone dependent breast cancer. Androstenedione, Adrenal dehydroepiandrosterone sulfate and estrone-sulfate also plays an important role of precursor for estrogen biosynthesis. Estrogens deprivation exhibits an attractive phenomena in the advancement of most ideal therapeutics for the treatment of breast cancer. Inhibition of aromatase and sulphatase emerged as attractive therapy for the treatment of hormone dependent breast cancer via deprivation of estrogen by different pathways. The cocktail of aromatase and sulphatase inhibitors known as dual aromatase-sulphatase inhibitors (DASIs) emerged as an attractive approach for the effective estrogen deprivation. The present review article focused on the journey of dual aromatase-sulphatase inhibitors from the beginning to till date (2020). Keeping in view the key observations, this review may be helpful for medicinal chemists to design and develop new and efficient dual aromatase-sulphatase inhibitors for the possible treatment of hormone-related breast cancer.

Sign in / Sign up

Export Citation Format

Share Document